• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Robert C Doebele, Amanda B. Pilling, +9 authors David Ross Camidge
  • Biology, Medicine
  • Clinical Cancer Research
  • 2012 (First Publication: 10 January 2012)
  • Purpose: Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest dramatic responses to crizotinib, a small-molecule ALK inhibitor. Unfortunately, not every patient respondsContinue Reading
  • David Ross Camidge, Y Bang, +21 authors Alice Tsang Shaw
  • Medicine
  • The Lancet. Oncology
  • 2012 (First Publication: 1 October 2012)
  • BACKGROUND ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs). We assessed the tolerability and activity of crizotinib in patients with NSCLC who were prospectively identifiedContinue Reading
  • Jennifer L. Spratlin, Roger B. Cohen, +14 authors Stephan Eckhardt
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2010 (First Publication: 10 February 2010)
  • PURPOSE To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics, and preliminary anticancer activity of ramucirumab (IMC-1121B), a fully human immunoglobulinContinue Reading
  • Alice Tsang Shaw, Beow Yong Yeap, +20 authors David Ross Camidge
  • Medicine
  • The Lancet. Oncology
  • 2011 (First Publication: 1 October 2011)
  • BACKGROUND ALK gene rearrangement defines a new molecular subtype of non-small-cell lung cancer (NSCLC). In a recent phase 1 clinical trial, the ALK tyrosine-kinase inhibitor (TKI) crizotinib showedContinue Reading
  • Jacob J. Chabon, Andrew D Simmons, +19 authors Maximilian Diehn
  • Biology, Medicine
  • Nature communications
  • 2016 (First Publication: 10 June 2016)
  • Circulating tumour DNA (ctDNA) analysis facilitates studies of tumour heterogeneity. Here we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in 43 non-small cell lung cancer (NSCLC)Continue Reading
  • Dong-Wan Kim, Marcello Tiseo, +17 authors David Ross Camidge
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2017 (First Publication: 5 May 2017)
  • Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene ( ALK)-rearranged non-small-cell lung cancer (ALK-positive NSCLC) eventually experience disease progression. We evaluatedContinue Reading
  • Yelena Y Janjigian, Egbert Frederik Smit, +9 authors William Pao
  • Biology, Medicine
  • Cancer discovery
  • 2014 (First Publication: 1 September 2014)
  • UNLABELLED EGFR-mutant lung cancers responsive to reversible EGFR inhibitors (gefitinib/erlotinib) develop acquired resistance, mediated by second-site EGFR T790M mutation in >50% of cases.Continue Reading